WOVEN-PLANET-HOLDINGS
23.3.2022 05:32:09 CET | Business Wire | Press release
ENEOS Corporation (ENEOS) and Toyota Motor Corporation (Toyota) have signed a joint agreement to explore CO2 -free hydrogen production and usage at Woven City, the prototype city of the future that Toyota has started to develop in Susono City, Shizuoka Prefecture, Japan. Together with Toyota’s subsidiary Woven Planet Holdings, Inc. (Woven Planet), they will accelerate efforts by managing technical logistics.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220322006181/en/
As described in the Basic Agreement signed in 2021, ENEOS and Toyota have decided to commence construction and operation of a hydrogen refueling station in close proximity to Woven City to produce and supply CO2 -free hydrogen to Woven City and Fuel Cell Electric Vehicles (FCEVs) (Item 1 and 2 set forth below). Together, they will also research and design an efficient hydrogen supply and demand management system (Item 3 described below). The ENEOS hydrogen refueling station is scheduled to begin operations before the opening of Woven City in 2024-2025.
Items to be considered at the time of the Basic Agreement*1
- ENEOS to establish and operate a hydrogen refueling station in close proximity to Woven City
- ENEOS to produce "green hydrogen," hydrogen derived from renewable energy, by electrolyzers at the aforementioned station and supply it to Woven City to be used at a stationary fuel cell generator that will be installed within Woven City by Toyota
- Promote the use of hydrogen-powered fuel cell mobility for logistics in and nearby Woven City. Validate a base unit*2 of hydrogen demand for those mobility logistics as well as build a supply and demand management system
- Conduct joint advanced research on hydrogen supply at the demonstration hub to be established within Woven City
Items that have been decided in the joint development agreement this time
Item 1) |
- Construct a hydrogen refueling station adjacent to Woven City (Scheduled to be constructed at 1576-3, Mishuku Aza Hounokidaira, Susono-city, Shizuoka-Pref., Japan) |
Item 2) |
- Install electrolyzers at the hydrogen refueling station, which will produce CO2 -free hydrogen using electricity generated by renewable energy - Supply CO2 -free hydrogen to not only various FCEVs from passenger cars to commercial vehicles but also to Woven City using a pipeline - Install a stationary fuel cell generator at the hydrogen refueling station in case of a power outage*3 |
Item 3) |
- Consider connecting the Community Energy Management System (CEMS) of Woven City with the hydrogen EMS of ENEOS to optimize hydrogen production |
The ENEOS hydrogen refueling station will “produce” the hydrogen that will meet the energy needs of “users,” FCEVs in and around Woven City and Woven City as well. This collaboration expedites our progress toward realizing a truly carbon-neutral society and will facilitate and normalize clean energy operations first at Woven City and eventually the world.
Woven City is the project of Toyota aiming to create happiness through mobility of "people," "goods," and "information." It is focused on three pillars. That are: Human-Centered City that makes people happier in their everyday lives, considering the needs of different kinds of people before and during the development of technology; Living Laboratory, the first-of-its-kind test track for mobility where researchers, engineers, and scientists demonstrate innovative ideas and future technologies both virtually and in the real world; and Ever-Evolving City, rooted in Toyota’s kaizen (continuous improvement) approach, is focused on new ideas that provide better mobility of information, goods, and people.
*1 Announced on May 10, 2021 “ENEOS and Toyota Come Together to Make Woven City the Most Hydrogen-Based Society”
*2 Hydrogen can be supplied to FCEVs even during power outages by using stored hydrogen to operate a hydrogen refueling system with a stationary fuel cell generator. This allows the external power supply function of FCEVs to be utilized to provide power support where electricity is needed.
*3 The "base unit" is a standard of measurement required to ensure a result that is both practically valuable to users and commercially viable.
About ENEOS Corporation
Under ENEOS Holdings, Inc., the ENEOS Group has developed businesses in the energy and nonferrous metals segments, from upstream to downstream. The Group's envisioned goals for 2040 are: becoming one of the most prominent and internationally-competitive energy and materials company groups in Asia, creating value by transforming our current business structure, and contributing to the development of a low-carbon, recycling-oriented society with the pursuit of carbon-neutral status in its own CO2 emissions. ENEOS Corporation, one of the principal operating companies in the Group, is contributing to achievement of the Group's envisioned goals through a broad range of energy businesses.
https://www.hd.eneos.co.jp/english/
https://www.eneos.co.jp/english/
About Toyota Motor Corporation
Toyota Motor Corporation (Toyota) (NYSE: TM) is the global mobility company that introduced the Prius hybrid-electric car in 1997 and the first mass-produced fuel cell sedan, Mirai, in 2014. Headquartered in Toyota City, Japan, Toyota has been making cars since 1937. Today, Toyota proudly employs 370,000 employees in communities around the world. Together, they build around 10 million vehicles per year in 28 countries and regions, from mainstream cars and premium vehicles to mini-vehicles and commercial trucks, and sell them in more than 170 countries and regions under the brands Toyota, Lexus, Daihatsu and Hino.
For more information, please visit https://global.toyota/en
Woven Planet
Woven Planet is building the safest mobility in the world. A subsidiary of Toyota, Woven Planet innovates and invests in new technologies, software, and business models that transform how we live, work and move. With a focus on automated driving, smart cities, robotics and more, Woven Planet builds on Toyota's legacy of trust to deliver secure, connected, reliable, and sustainable mobility solutions for all.
Learn more at woven-planet.global.
End
View source version on businesswire.com: https://www.businesswire.com/news/home/20220322006181/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom